Page 1 2
Patients should choose a payment option by checking the appropriate box on the 
OnDose Test Request Form. If the Insurance Billing option is selected, the patient's signature is also required. The OnDose Test Request Form is available in every test kit or by calling Myriad Customer Service at 1-800-469-7423 (option "0").
Payment options are outlined below:
Option 1—Insurance Billing
Myriad Genetic Laboratories, Inc., will bill the insurer for services rendered. Testing will begin upon receipt of the plasma sample, completed OnDose Test Request Form (with patient signature), and legible photocopies of the front and back of the patient's insurance card. Myriad Genetic Laboratories, Inc., will submit bills directly to insurance carriers and will appeal and resubmit claims if necessary.
Option 2—Patient Payment
Alternatively, patients may pay for the testing service themselves. Patients may provide credit card information on the OnDose Test Request Form or provide a check or money order payable to Myriad Genetic Laboratories, Inc., for submission in the test kit together with the plasma sample. Patients may also contact Myriad Customer Service at 1-800-469-7423 for installment payment options.
OnDose Patient Protection Program
For a limited time, Myriad Genetic Laboratories, Inc., will be offering the OnDose Patient Protection Program. This program is designed to protect patients undergoing infusional 5-FU chemotherapy from unexpected financial liability due to limited insurance coverage during the introduction of OnDose.
Qualifying patients* who have received OnDose may apply for the program. Patients will continue to be responsible for applicable deductibles and copayment amounts according to their health plans. However, copayment costs for OnDose will be limited to 20% of the billed charges from Myriad after applicable deductibles have been met.
Eligibility
To participate, qualifying patients* who opted for insurance billing as described above may, after receiving an invoice from Myriad Genetic Laboratories, Inc., contact the Myriad billing department at 1-800-725-2722 to complete a program application. In the case of an insurance denial, the patient must agree to cooperate with Myriad's appeal to the insurance company for coverage.
Letters of Medical Necessity
Some insurance companies require that a letter of medical necessity (LMN) be submitted before granting preauthorization. An example of an LMN can be viewed by clicking the following link:
Page 1 2
*A qualifying patient is one who is currently receiving infusional 5-FU-based chemotherapy as a result of a cancer diagnosis, is a member of a private health insurance plan, and resides in a jurisdiction where such a program is not prohibited by law. The Patient Protection Program is not available to patients covered under Medicare, Medicaid, or other government programs, or those who reside in Florida, Massachusetts, Texas, Minnesota, Rhode Island, or other states where such a program is prohibited.
